RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Applied Therapeutics Stock

Applied Therapeutics Revenue 2024

Applied Therapeutics Revenue

1.74 M USD

Ticker

APLT

ISIN

US03828A1016

WKN

A2PHHB

In 2024, Applied Therapeutics's sales reached 1.74 M USD, a -82.64% difference from the 9.99 M USD sales recorded in the previous year.

The Applied Therapeutics Revenue history

YEARREVENUE (undefined USD)GROSS MARGIN (%)
2029e487.69-
2028e396.55-
2027e282.29-
2026e151.1-
2025e59.85-
2024e1.74-
20239.99-
2022--
2021--
2020--
2019--
2018--
2017--

Applied Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Applied Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Applied Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Applied Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Applied Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Applied Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Applied Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Applied Therapeutics’s growth potential.

Applied Therapeutics Revenue, EBIT and net profit per share

DateApplied Therapeutics RevenueApplied Therapeutics EBITApplied Therapeutics Net Income
2029e487.69 M undefined0 undefined176.89 M undefined
2028e396.55 M undefined180.77 M undefined125.35 M undefined
2027e282.29 M undefined87.8 M undefined62.09 M undefined
2026e151.1 M undefined9.03 M undefined16.61 M undefined
2025e59.85 M undefined-59.24 M undefined-52.54 M undefined
2024e1.74 M undefined-89.58 M undefined-112.17 M undefined
20239.99 M undefined-64.54 M undefined-119.76 M undefined
20220 undefined-82.95 M undefined-82.51 M undefined
20210 undefined-105.62 M undefined-105.58 M undefined
20200 undefined-94.47 M undefined-93.96 M undefined
20190 undefined-45.58 M undefined-45.51 M undefined
20180 undefined-13.52 M undefined-16.52 M undefined
20170 undefined-4.29 M undefined-4.28 M undefined

Applied Therapeutics stock margins

The Applied Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Applied Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Applied Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Applied Therapeutics's sales revenue. A higher gross margin percentage indicates that the Applied Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Applied Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Applied Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Applied Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Applied Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Applied Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Applied Therapeutics Margin History

Applied Therapeutics Gross marginApplied Therapeutics Profit marginApplied Therapeutics EBIT marginApplied Therapeutics Profit margin
2029e0 %0 %36.27 %
2028e0 %45.59 %31.61 %
2027e0 %31.1 %21.99 %
2026e0 %5.97 %10.99 %
2025e0 %-98.98 %-87.79 %
2024e0 %-5,163.07 %-6,465.03 %
20230 %-645.8 %-1,198.47 %
20220 %0 %0 %
20210 %0 %0 %
20200 %0 %0 %
20190 %0 %0 %
20180 %0 %0 %
20170 %0 %0 %

Applied Therapeutics Aktienanalyse

What does Applied Therapeutics do?

Applied Therapeutics Inc is a biopharmaceutical company that focuses on developing therapies for chronic and specific serious diseases. The company was founded in 2016 by Shoshana Shendelman, who is also the CEO of the company. Applied Therapeutics is headquartered in New York City and currently employs over 50 employees. The business model of Applied Therapeutics is designed to address gaps in current medical care and develop novel therapies that do not yet exist. The company invests heavily in research and development to find new drugs and therapies that are more effective and safer than existing treatment methods. Applied Therapeutics has focused on developing drugs that can be used in the areas of neurological and cardiovascular diseases, as well as metabolic diseases. The main products currently under development aim to treat metabolic diseases such as diabetic neuropathy and mucopolysaccharidosis (MPS). The company has a broad portfolio of technologies, including the targeted protein degrader platform, which aims to degrade critical proteins that play a role in certain diseases. Applied Therapeutics also uses genomics to gain a deeper understanding of the underlying causes of diseases. By identifying targets for new drugs and therapies, the company also uses AI algorithms to select promising candidates for clinical trials. Applied Therapeutics' particular expertise lies in the research of molecules that play a key role in regulating carbohydrate metabolism and energy production in the body. Applied Therapeutics' medications aim to selectively regulate these critical molecules and thus combat various diseases. The first product from Applied Therapeutics is AT-001, a medication for the treatment of diabetic neuropathies. A phase II study has shown that AT-001 provides a significant improvement in neuropathic pain and sensitivity. The medication is currently being tested in a phase III clinical trial. Another promising class of drugs from Applied Therapeutics is the SGLT2 inhibitor, which targets carbohydrate metabolism and thus covers a wide range of diseases, from diabetes to cardiovascular diseases. Applied Therapeutics has also signed a license agreement with the University of Minnesota for the development of medications for the treatment of MPS I. In this collaboration, the company brings its expertise in molecules regulating carbohydrate and energy metabolism to develop a new treatment for MPS patients. It is important to mention that Applied Therapeutics' drugs are still in development and are in various stages of clinical trials. After completing the clinical trials and potential FDA approval, the products must also be brought to market, which can pose additional challenges. Overall, Applied Therapeutics has focused on developing therapies for chronic and serious diseases. The company has a broad portfolio of technologies aimed at combating the underlying causes of diseases. With AT-001 already on the market, the company has brought a promising medication to market, and additional products are in development. Whether the company will meet its ambitious goals remains to be seen, but there is no doubt that it operates in an exciting area with great potential. Applied Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding Applied Therapeutics's Sales Figures

The sales figures of Applied Therapeutics originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Applied Therapeutics’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Applied Therapeutics's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Applied Therapeutics’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Applied Therapeutics stock

How much revenue did Applied Therapeutics generate this year?

Applied Therapeutics has achieved a revenue of 1.74 M USD this year.

How much was the turnover of the company Applied Therapeutics compared to the previous year?

The revenue of Applied Therapeutics has increased by -82.64% decreased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of Applied Therapeutics?

The revenue of Applied Therapeutics is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of Applied Therapeutics measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of Applied Therapeutics so important for investors?

The revenue of Applied Therapeutics is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does Applied Therapeutics pay?

Over the past 12 months, Applied Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Applied Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Applied Therapeutics?

The current dividend yield of Applied Therapeutics is .

When does Applied Therapeutics pay dividends?

Applied Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Applied Therapeutics?

Applied Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Applied Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Applied Therapeutics located?

Applied Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Applied Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Applied Therapeutics from 9/29/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/29/2024.

When did Applied Therapeutics pay the last dividend?

The last dividend was paid out on 9/29/2024.

What was the dividend of Applied Therapeutics in the year 2023?

In the year 2023, Applied Therapeutics distributed 0 USD as dividends.

In which currency does Applied Therapeutics pay out the dividend?

The dividends of Applied Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Applied Therapeutics stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Applied Therapeutics

Our stock analysis for Applied Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Applied Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.